牛磺鹅去氧胆酸
| 中文名称 | 牛磺鹅去氧胆酸 |
|---|---|
| 中文同义词 | 牛磺鹅去氧胆酸;TAUROCHENODEOXYCHOLIC ACID 牛磺鹅去氧胆酸 英文名称: 2-[4-(3,7-DIHYDROXY-10,13- CAS号: 516-35-8 分子式: C26H45NO6S 分子量: 499.7 含量98% 白色粉末 牛磺鹅去氧胆酸钠用于生化研究;纯天然牛磺鹅去氧胆酸含量98% 白色粉末 中文同义词: 牛磺鹅去氧胆酸;【纯天然牛磺鹅去氧胆酸】医药含量95%白色粉末;纯天然牛磺鹅去氧胆酸;【纯天然牛磺鹅去氧胆酸】医药含量98%白色粉末;牛磺鹅脱氧胆酸(牛磺鹅去氧胆酸);TAUROCHENODEOXYCHOLIC ACID 牛磺鹅去氧胆酸 |
| 英文名称 | Taurochenodeoxycholic acid |
| 英文同义词 | 2-(4-(3,7-dihydroxy-10,13-diMethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanaMido)ethanesulfonic acid;Taurocholic chenodeoxycholic acid;2-((R)-4-((3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-Dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethanesulfonic acid;2-[4-(3,7-dihydroxy-10,13-;Taurochenodeoxycholic acid;C05465;Chenodeoxycholoyltaurine;12-Deoxycholyltaurine |
| CAS号 | 516-35-8 |
| 分子式 | C26H45NO6S |
| 分子量 | 499.7 |
| EINECS号 | |
| 相关类别 | 中药对照品;对照品、标准品;对照品;植物提取物;标准品;原料药;医药原料;其他原料;分析试剂标准品;对照品-中药对照品;标准品 -中药标准品;标准品，对照品;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Steroids;分析试剂标准品 |
| Mol文件 | 516-35-8.mol |
| 结构式 |  |
牛磺鹅去氧胆酸 性质
| 熔点 | 186-200°C |
|---|---|
| 密度 | 1.216±0.06 g/cm3(Predicted) |
| 储存条件 | Sealed in dry,Room Temperature |
| 溶解度 | 可溶于氯仿、甲醇 |
| 形态 | 固体 |
| 酸度系数(pKa) | 1.42±0.50(Predicted) |
| 颜色 | 白色至浅棕色 |
|
Human Endogenous Metabolite
|
Taurochenodeoxycholic acid (12-Deoxycholyltaurine) dramatically improves the apoptosis rate of NR8383 cells in a concentration-dependent manner. In the meantime, Taurochenodeoxycholic acid significantly augments PKC mRNA levels, activities and increases JNK, caspase-3 and caspase-8 mRNA expression levels, activities.
Taurochenodeoxycholic acid (12-Deoxycholyltaurine; 0.05, 0.1g/kg) decreases the pulmonary coefficient in the model mice and reduces the pathological damages on their lungs; it can decrease the expression levels of TNF-α and TIMP-2 in pulmonary tissues in the pulmonary fibrosis mice and has no significant effects on MMP2.
Taurochenodeoxycholic acid significantly normalizes the clinical inflammatory parameters, prevented indomethacin-induced increases in the biliary contents of secondary bile acids and hydrophobicity index, and tended to attenuate the intestinal inflammation.
Taurochenodeoxycholic acid significantly suppresses paw swelling and polyarthritis index, increases the loss body weight and index of thymus and spleen, and amends radiologic changes in AA rats. The overproduction and mRNA expression of TNF-α, IL-1β and IL-6 are remarkably suppressed in serum and synovium tissue of all TCDCA-treated rats.